PATENT CLAIM ANALYSIS

Application Number: 16073787
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["530", "387900"]

Abstract:
The present invention relates to an antibody or antigen-binding fragment thereof against EGFRvIII (Epidermal Growth Factor Receptor Variant III), a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for producing the antibody or antigen-binding fragment thereof, a composition for preventing or treating cancer, which comprises the same, a composition for diagnosing cancer, which comprises the same, and a kit for diagnosing cancer, which comprise the composition for diagnosing cancer.

Claim (Index 13):
A composition for diagnosing cancer, which comprises the antibody or antigen-binding fragment thereof according to  claim 1 .

Metadata:
- Claim Count in Document: 13.0
- Percentile: 95.0
- Lexical Diversity: 1.97872
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15170628', '14643886', '15528753', '10877773', '10877774']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7383235116387428
- 35 USC 102 Novelty (BERT): 0.5331870361935578
- Combined Prediction Score: 0.7178098640942243
- Mean Citation Score: 360.440586
- Max Citation Score: 373.8334
- Similarity Product: 310.06328328564166

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test